Fulcrum Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Fulcrum Therapeutics's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 56% to $2,805,000. The net income raised on -$97,335,000 and profit margin reached -3470%. Total operating expenses were $113,469,000.
Profit Margin
| 2017 | 0 | -22.96M | |
|---|---|---|---|
| 2018 | 0 | -32.58M | |
| 2019 | 0 | -79.11M | |
| 2020 | 8.82M | -68.44M | -775.7% |
| 2021 | 19.16M | -78.33M | -408.77% |
| 2022 | 6.34M | -105.62M | -1665.42% |
| 2023 | 2.80M | -97.33M | -3470.05% |
FULC Income Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Revenue | |||||||
Revenue | 2.80M | 6.34M | 19.16M | 8.82M | 0 | 0 | 0 |
Cost of revenue | 0 | 2.41M | 2.51M | 2.37M | 2.05M | 0 | 715K |
Gross profit | 2.80M | 3.92M | 16.64M | 6.44M | -2.05M | 0 | -715K |
Operating exp. | |||||||
Research and development | 71.80M | 76.78M | 69.70M | 59.04M | 71.07M | 25.18M | 18.49M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 113.46M | 118.47M | 100.21M | 80.43M | 84.21M | 33.49M | 22.99M |
Operating income | -110.66M | -112.56M | -81.05M | -71.61M | -84.21M | -33.49M | -22.99M |
Other income (expenses), net | 13.32M | 2.69M | 207K | 792K | 1.54M | 392K | 29K |
Income before tax | -97.33M | -109.87M | -80.84M | -70.81M | -82.67M | -32.58M | -22.96M |
Income tax expense | 0 | -4.25M | -2.51M | -2.37M | -3.56M | 910K | -1K |
Net income | -97.33M | -105.62M | -78.33M | -68.44M | -79.11M | -32.58M | -22.96M |
Earnings per share | |||||||
Basic EPS | -1.59 | -2.35 | -2.22 | -2.7 | -7.16 | -1.92 | -2.1 |
Diluted EPS | -1.59 | -2.35 | -2.22 | -2.7 | -7.16 | -1.92 | -2.1 |
| Data source | Data source | Data source | Data source | Data source |